What is Amnio Technology?
Amnio Technology is a prominent developer and manufacturer of amnion-derived technologies, specializing in high-quality, chorion-free products designed to mitigate graft-versus-host autoimmune responses. The company is committed to pioneering regenerative therapies for critical unmet needs within wound care and orthopedics. Their product portfolio features a range of amniotic allografts, marketed under the PalinGen brand, engineered for both ease of use and therapeutic effectiveness. Amnio Technology's commitment to stringent quality and regulatory standards has earned the trust of hospitals and clinics across the nation.
How much funding has Amnio Technology raised?
Amnio Technology has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Amnio Technology
PPP
Public-Private Partnership
What's next for Amnio Technology?
With its recent large-scale late-stage funding, Amnio Technology is poised for significant expansion and further innovation in regenerative therapies. The strategic investment will likely fuel advancements in product development, enhance manufacturing capabilities, and broaden market penetration for their PalinGen line of amniotic allografts. This capital infusion signals strong investor confidence in Amnio Technology's mission to address complex medical challenges in wound care and orthopedics, positioning the company for sustained growth and leadership in the regenerative medicine landscape.
See full Amnio Technology company page
